Drugs Containing Excipient (Inactive Ingredient) BUTYL ESTER OF METHYL VINYL ETHER-MALEIC ANHYDRIDE COPOLYMER

« Back to Dashboard

Generic drugs containing BUTYL ESTER OF METHYL VINYL ETHER-MALEIC ANHYDRIDE COPOLYMER excipient

Company	Ingredient	NDC	Excipient
Physicians Total Care Inc	ciclopirox	54868-6064	BUTYL ESTER OF METHYL VINYL ETHER-MALEIC ANHYDRIDE COPOLYMER

Butyl Ester of Methyl Vinyl Ether-Maleic Anhydride Copolymer Market Dynamics and Financial Trajectory

Last updated: August 3, 2026

Butyl ester of methyl vinyl ether-maleic anhydride copolymer is a specialty pharmaceutical excipient used primarily for mucoadhesion, film formation, taste masking, controlled release, and dental drug-delivery systems. The material is commonly associated with the Gantrez ES product family, including Gantrez ES-425 NF. Its market is small, formulation-driven, and supplier-concentrated. Public financial statements do not report revenue for this individual excipient, so its financial trajectory must be assessed through end-market demand, formulation adoption, pricing, manufacturing capacity, and supplier portfolio performance.

What is butyl ester of methyl vinyl ether-maleic anhydride copolymer?

Butyl ester of methyl vinyl ether-maleic anhydride copolymer is a partially esterified poly(methyl vinyl ether-co-maleic anhydride), also called PVM/MA butyl ester or butyl ester of PVM/MA copolymer. Its commercial identity is often linked to Gantrez ES grades supplied by Ashland.

Attribute	Market description
Chemical family	Poly(methyl vinyl ether-co-maleic anhydride) ester
Common name	Butyl ester of PVM/MA copolymer
Typical commercial association	Gantrez ES-425 NF and related grades
Excipient functions	Mucoadhesive polymer, film former, binder, taste-masking aid, controlled-release matrix component
Principal dosage-form relevance	Oral films, buccal systems, dental products, oral suspensions, topical and transmucosal systems
Regulatory status	Pharmaceutical excipient use depends on grade, route, formulation, and jurisdiction
Market structure	Specialty, qualification-intensive, supplier-concentrated
Public revenue disclosure	Not available at individual excipient level

The polymer contains carboxylic acid functionality derived from the maleic anhydride segment and hydrophobic butyl ester groups. This combination gives the material adhesion to biological surfaces, film-forming performance, water-responsive behavior, and compatibility with selected active pharmaceutical ingredients.

Ashland describes Gantrez polymers as multifunctional excipients used in oral care, pharmaceutical, and drug-delivery applications. Product-specific performance depends on molecular weight, esterification level, residual solvent profile, particle properties, and manufacturing grade. [1]

What pharmaceutical applications drive demand?

Demand comes from formulations that require adhesion, residence time, film strength, or controlled interaction with water. Conventional tablet formulations generally have lower demand for this polymer than specialized delivery systems.

Mucoadhesive and transmucosal drug delivery

The polymer can increase residence time on mucosal surfaces, including the buccal and sublingual regions. It is relevant to oral films and other systems designed to release an active ingredient locally or systemically.

The commercial opportunity is strongest where a formulation sponsor needs:

• Longer residence at the administration site
• Improved bioavailability
• Reduced dosing frequency
• A noninvasive alternative to injection
• Taste masking in pediatric or geriatric products
• Rapid disintegration with controlled adhesion

Commercial adoption remains formulation-specific. A polymer may perform well in laboratory testing but fail during scale-up because of film brittleness, moisture sensitivity, processing variability, or interaction with the active ingredient.

Dental and oral-care products

PVM/MA copolymers are established in dental and oral-care applications because they can form films and interact with tooth or mucosal surfaces. Pharmaceutical-grade material may be used where a product requires controlled release, adhesion, or local retention.

Dental products provide a more stable demand base than novel transmucosal medicines because they are sold in recurring consumer and professional channels. The pharmaceutical value per kilogram can be higher, but qualification cycles are longer.

Oral films and taste masking

The polymer can support thin-film dosage forms and help retain active ingredients at the site of administration. Taste masking is commercially important for pediatric products, orally disintegrating systems, and products containing bitter or metallic-tasting compounds.

The main competitive materials include cellulose derivatives, polyacrylates, povidone, polyethylene oxide, alginates, carbomers, and other mucoadhesive polymers. Selection is usually driven by performance rather than unit price alone.

How large is the market for this excipient?

No authoritative public source reports a standalone global market size for butyl ester of methyl vinyl ether-maleic anhydride copolymer. Commercial market reports typically aggregate the material into broader categories such as pharmaceutical polymers, mucoadhesive excipients, oral drug-delivery polymers, or specialty excipients.

This limits the reliability of market-size claims. A defensible assessment is that the material is a niche excipient with demand measured in specialty-industrial volumes rather than commodity-scale volumes. The market value is supported by high qualification barriers and technical switching costs, not by large tonnage.

Market structure

The market has four defining characteristics:

1. Supplier concentration is high because pharmaceutical customers require consistent chemistry, documentation, and change-control support.
2. Demand is concentrated in a limited number of formulations and product platforms.
3. New customer qualification can take years because excipient changes may trigger stability, bioequivalence, safety, or regulatory work.
4. A small number of commercial products can account for a disproportionate share of demand.

This structure limits rapid volume expansion but supports pricing stability when the supplier maintains quality and reliable supply.

What factors are changing market demand?

Growth drivers

Demand can increase through:

• Growth in oral thin films and buccal delivery
• Pediatric and geriatric dosage-form development
• Increased use of polymeric excipients in modified-release products
• Expansion of local oral and dental therapies
• Reformulation to improve adherence or reduce dosing frequency
• Development of combination products requiring site-specific retention
• Greater use of excipient functionality to reduce active pharmaceutical ingredient load

The strongest opportunity is in products where the polymer changes clinical or commercial performance. A formulation that merely uses the polymer as a low-cost binder has weaker pricing power.

Demand constraints

The market faces several structural constraints:

• Limited number of approved or late-stage products
• Competition from lower-cost polymers
• Long formulation-development timelines
• Regulatory scrutiny of novel excipient use
• Moisture and process sensitivity in film systems
• Potential variability among polymer grades
• Limited public visibility into supply and demand

The excipient is also exposed to project cancellations. If a development program using the polymer fails, demand can disappear before commercial launch.

What is the financial trajectory for this excipient?

The financial trajectory is best described as stable-to-growth oriented in value, with low visibility and modest volume expansion. The material is unlikely to follow the rapid growth profile of a high-volume excipient such as microcrystalline cellulose or hypromellose. Its financial performance depends on mix, qualification wins, and commercial product retention.

Financial driver	Expected effect
New oral-film or buccal product approvals	High positive effect
Retention of qualified commercial products	Recurring revenue support
Raw-material inflation	Margin pressure unless passed through
Energy and specialty-polymer manufacturing costs	Margin volatility
Single-source customer dependence	Revenue concentration risk
Supplier consolidation	Potential pricing power
Generic substitution	Moderate, depending on formulation complexity
Regulatory requalification after change	Potential volume disruption
Expansion into nonpharmaceutical applications	Portfolio diversification

Revenue trajectory

Individual excipient revenue is not disclosed by Ashland or other public suppliers. Ashland reports broader business segments rather than sales for Gantrez ES grades. [2] Any precise revenue forecast for this polymer would therefore be an estimate rather than a reported financial metric.

The likely trajectory has three stages:

• Near term: Stable base demand from existing dental, oral-care, and pharmaceutical customers, with price increases tied to manufacturing and quality costs.
• Medium term: Incremental growth if oral-film, buccal, and pediatric products reach commercial scale.
• Long term: Uneven growth because individual product launches can create sharp increases followed by maturity or discontinuation.

Margin profile

Specialty excipients generally support higher gross margins than commodity excipients because customers pay for qualification, consistency, regulatory files, and technical service. The margin profile can weaken when:

• The polymer requires complex esterification or purification
• Batch sizes are small
• Customers demand extensive testing
• Raw-material costs rise
• The supplier maintains redundant capacity
• A major customer negotiates volume-based pricing

The highest-value sales are pharmaceutical-grade products with validated specifications and regulatory support. Lower-grade or nonpharmaceutical applications face greater price competition.

Which companies supply or compete with this polymer?

Ashland is the most visible commercial supplier associated with the Gantrez polymer family. Public product literature identifies Gantrez grades for pharmaceutical and personal-care applications. [1]

Competition comes from both direct and functional substitutes.

Direct competitive set

The direct competitive set includes other grades of PVM/MA copolymers, including acid, sodium salt, and esterified variants. These products may differ in water solubility, adhesion, viscosity, film strength, and release behavior.

Functional substitutes

Functional requirement	Competing excipient classes
Mucoadhesion	Carbomers, polycarbophil, chitosan, sodium alginate, cellulose derivatives
Film formation	Hydroxypropyl methylcellulose, pullulan, PVA, PVP
Controlled release	Ethylcellulose, methacrylate copolymers, lipid matrices
Taste masking	Coating polymers, ion-exchange resins, lipid systems
Dental adhesion	Carbomers, polyacrylic acids, cellulose polymers

The principal commercial risk is functional substitution. A customer does not need to replace the polymer with a chemically similar material. It can redesign the dosage form around a different polymer if that option lowers cost or simplifies regulatory support.

What regulatory status applies to butyl ester of PVM/MA copolymer?

FDA excipient status is route- and use-dependent. Inclusion in the FDA Inactive Ingredient Database can support a regulatory assessment, but it does not create blanket approval for every dosage form, concentration, or route. [3]

For a product sponsor, the key regulatory questions are:

• Whether the exact grade has prior use in the proposed route
• Whether the concentration falls within established precedent
• Whether the supplier can provide pharmaceutical-grade specifications
• Whether residual monomers, solvents, catalysts, and impurities are controlled
• Whether the polymer has adequate toxicology and extractables data
• Whether the proposed use is compatible with FDA, EMA, and other regional requirements

The European Medicines Agency’s excipient guidance emphasizes quality, safety, functionality, and control of excipient characteristics in the finished product. [4]

What patents protect this excipient and its applications?

The polymer itself is an established chemical class, and broad foundational composition patents are unlikely to be the primary source of current commercial protection. The more relevant intellectual-property barriers are:

• Grade-specific manufacturing methods
• Molecular-weight and esterification controls
• Purification processes
• Particle engineering
• Polymer-active pharmaceutical ingredient complexes
• Mucoadhesive dosage forms
• Oral-film compositions
• Dental delivery systems
• Controlled-release formulations

Patent protection is therefore more likely to attach to a formulation or manufacturing process than to the generic chemical identity of the butyl ester polymer.

Orange Book and Paragraph IV relevance

The excipient itself is not an FDA-approved drug product and ordinarily is not listed in the Orange Book as an active pharmaceutical ingredient. [5] It does not independently create an Orange Book patent barrier.

Paragraph IV litigation may arise when a generic drug product uses the polymer in a patented formulation or method of use. The risk attaches to the finished drug’s listed patents, not automatically to the excipient supplier or the polymer chemistry.

Biosimilar risk

Biosimilar competition is generally not a direct demand driver for this excipient. The polymer is more relevant to small-molecule oral, transmucosal, dental, or topical products than to injectable biologics. It could be used in a biologic delivery platform, but that is not the principal commercial market.

What manufacturing and IP barriers affect market entry?

Manufacturing entry requires more than reproducing the monomer ratio. A credible pharmaceutical supplier must control:

• Polymerization conditions
• Esterification level
• Molecular-weight distribution
• Residual maleic anhydride and monomer content
• Solvent residues
• Moisture
• Particle-size distribution
• Microbial quality
• Batch-to-batch adhesive and film-forming performance

A new supplier also must establish a regulatory package, audit readiness, stability data, change-control procedures, and supply continuity. These requirements create a meaningful entry barrier even where composition-level patent protection is limited.

Geographic coverage is another barrier. Pharmaceutical customers generally prefer suppliers capable of supporting North American, European, and Asian regulatory filings, with documented manufacturing sites and dependable logistics. Regional production can lower freight costs but may not overcome the qualification advantage of an established global supplier.

What litigation and settlement issues affect the market?

No widely reported, excipient-specific Orange Book litigation or Paragraph IV settlement is associated with butyl ester of PVM/MA copolymer as a standalone material. Relevant disputes would more likely concern:

• Finished oral-film or buccal products
• Formulation patents using the polymer
• Trade secrets involving polymer manufacture
• Supply agreements and exclusivity
• Regulatory changes after manufacturing-site transfers
• Patent claims covering a drug-polymer complex

A customer’s patent estate can indirectly increase excipient demand if the polymer is difficult to replace without losing infringement protection or product performance.

What generic launch risks exist?

Generic entry can have mixed effects. A generic manufacturer may increase demand for the excipient if it copies a formulation that uses the polymer. The same manufacturer may instead redesign the dosage form to avoid formulation patents or reduce cost.

The principal risks are:

• Substitution with a lower-cost polymer
• Loss of a commercial drug product using the excipient
• Single-source procurement pressure
• Supplier change requiring regulatory filings
• Delayed generic launch caused by formulation complexity
• Patent expiry followed by price compression

For technically demanding oral films and mucoadhesive systems, generic substitution may be slower than in standard immediate-release tablets because performance depends on polymer grade and process conditions.

How strong is the commercial position of this excipient?

The commercial position is moderate to strong within its niche and weak as a broad-volume excipient. Its strengths are functional differentiation, customer qualification costs, and established use in specialized delivery systems. Its weaknesses are limited market scale, dependence on a small number of products, and the availability of substitute polymers.

Dimension	Assessment
Technical differentiation	Moderate to high
Supplier concentration	High
Volume growth	Low to moderate
Pricing power	Moderate in qualified pharmaceutical applications
Regulatory barrier	Moderate to high
Patent protection of chemical itself	Limited relevance
Formulation-level IP relevance	Potentially high
Generic exposure	Moderate
Biosimilar exposure	Low
Public financial transparency	Low

Key Takeaways

• Butyl ester of methyl vinyl ether-maleic anhydride copolymer is a niche, high-functionality pharmaceutical excipient associated with Gantrez ES grades.
• Its principal value is mucoadhesion, film formation, residence-time enhancement, taste masking, and specialized oral or dental delivery.
• No reliable public standalone market size or revenue figure is available for the material.
• Financial performance is likely driven by qualification wins, commercial product retention, specialty pricing, and supplier concentration.
• Ashland is the most visible commercial supplier linked to the product family.
• Direct chemical substitutes are less important than functional substitutes such as carbomers, cellulose polymers, PVP, pullulan, and methacrylate copolymers.
• The polymer itself is unlikely to create an Orange Book or Paragraph IV barrier. Formulation and method-of-use patents are more relevant.
• Manufacturing know-how, quality control, regulatory documentation, and customer qualification create the main barriers to entry.
• The most attractive growth channels are oral films, buccal delivery, pediatric dosage forms, and specialized dental or transmucosal products.
• The market outlook is stable to moderately positive in value, but individual product launches can produce uneven demand.

FAQs About Butyl Ester of Methyl Vinyl Ether-Maleic Anhydride Copolymer

Is butyl ester of PVM/MA copolymer the same as Gantrez ES-425 NF?

It is the chemical family associated with Gantrez ES grades. The exact equivalence depends on the supplier’s grade designation, specification, molecular-weight profile, esterification level, and pharmaceutical documentation.

Is this excipient used in tablets?

It can be used in tablet and oral-delivery systems, but its strongest commercial rationale is in specialized formulations requiring adhesion, film formation, taste masking, or controlled release.

Can a pharmaceutical company switch suppliers without regulatory work?

Usually not without assessment. A supplier change can affect polymer attributes, product performance, stability, and manufacturing controls. The regulatory impact depends on the product, jurisdiction, specification, and degree of equivalence.

Does this polymer have a drug master file?

A supplier may maintain a drug master file or equivalent confidential regulatory package, but the existence and scope of a file are supplier-specific. Public product literature alone does not establish the contents of a regulatory submission.

What is the largest commercial risk for the polymer?

The largest risk is formulation substitution or loss of a drug product that uses the material. Because the market depends on a limited number of specialized applications, a single product discontinuation can have a disproportionate effect on demand.

References

1. Ashland. (n.d.). Gantrez ES polymers: Pharmaceutical and personal care applications. Ashland Specialty Ingredients.

2. Ashland Global Holdings Inc. (2024). Annual report for the fiscal year ended September 30, 2024. Ashland Global Holdings Inc.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. Center for Drug Evaluation and Research.

4. European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.